Description

Biological therapy, also called immunotherapy, biological response modifier therapy, or biotherapy, uses the body’s immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Biological therapy for cancer is used in the treatment of many types of cancer to prevent or slow tumor growth and to prevent the spread of cancer. The global cancer biological therapy market is set to grow by US$ 37.45 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period, according to data and analytics company StrategyHelix. Rising geriatric population, rising incidence of cancer, favorable government regulations and market initiatives, increasing research & development activities are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cancer biological therapy. The global cancer biological therapy market is segmented on the basis of product, region. By product, it is categorized into monoclonal antibodies, vaccines, and CAR T-cell therapy. The monoclonal antibodies segment held the largest market share in 2020. By region, the cancer biological therapy market is divided into North America, Asia Pacific, Europe, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cancer biological therapy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


Report Scope

Product: monoclonal antibodies, vaccines, and CAR T-cell therapy
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027


Key Benefits for Stakeholders

Get a comprehensive picture of the global cancer biological therapy market
Pinpoint growth sectors and trends for investment
Understand what the future of the global cancer biological therapy market looks like
Identify the competitive landscape and window of opportunity


Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Cancer Biological Therapy Market by Product
4.1 Monoclonal Antibodies
4.2 Vaccines
4.3 Car T-Cell Therapy
5. Cancer Biological Therapy Market by Region
5.1 North America
5.2 Asia Pacific
5.3 Europe
5.4 Rest Of The World (Row)
6. Company Profiles
6.1 Amgen Inc.
6.2 AstraZeneca plc
6.3 Bristol-Myers Squibb Company (BMS)
6.4 Eli Lilly and Company
6.5 F. Hoffmann-La Roche AG
6.6 Genmab A/S
6.7 Gilead Sciences, Inc.
6.8 GlaxoSmithKline plc (GSK)
6.9 Janssen Pharmaceuticals, Inc.
6.10 Merck KGaA
6.11 Novartis International AG
6.12 Pfizer Inc.
7. Appendix
7.1 About StrategyHelix
7.2 Disclaimer


USD 2,750

Product Type

Industry Briefing

Release Date

5 November 2021

Region

Global

Pages

26

REQUEST SAMPLE

Global Cancer Biological Therapy Market 2021

Please fill out our form and we will get back to you.

CUSTOM RESEARCH

Global Cancer Biological Therapy Market 2021

Please fill out our form and we will get back to you.

login